个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Radiotherapy Improves Survival of Patients with Lymphovascular Invasion in pT1b Esophageal Squamous Cell Cancer after Endoscopic Submucosal Dissection

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yang Xu[1] * ; Zhao Lina[2] * ; Shi Anhui[3] * ; Chen Cong[4] * ; Cao Jianzhong[5] ; Zhang Yaowen[6] ; Zhu Hui[7] ; Wang Jun[8] ; Zhou Wei[9] ; Li Xiangpan[10] ; Hu Songliu[11] ; Men Yu[12] ; Wang Jianyang[13] ; Xue Liyan[14] ; Liu Yong[15] ; Dou Lizhou[15] ; Zhang Yueming[15] ; Sun Shuang[13] ; Yuan Meng[13] ; Bao Yongxing[13] ; Ma Zeliang[13] ; Liu Mm Yunsong[13] ; Zhang Mm Wanting[13] ; Bi Nan[13] ; Wang Guiqi[15,*1] ; Hui Zhouguang[12,*1] ;
机构： [1]Department of VIP Medical Services & Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [2]Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi'an, China. [3]Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China. [4]Department of Gastroenterology, the First Affiliated Hospital of Army Medical University, Chongqing, China. [5]Department of Radiation Oncology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Shanxi, China. [6]Department of Thoracic Oncology, Anyang Tumor Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Henan Medical key Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang, China. [7]Department of Radiation Oncology, Affiliated Cancer Hospital of Shandong First Medical University, Shandong, China. [8]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [9]Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China. [10]Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China. [11]Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. [12]Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [13]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [14]Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [15]Department of Endoscopy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
出处：
DOI： 10.14309/ajg.0000000000002257
ISSN：

关键词： Esophageal Cancer T1bN0M0 Endoscopic Submucosal Dissection Adjuvant Radiotherapy

摘要：
Adjuvant radiotherapy is recommended for pT1b esophageal squamous cell cancer (ESCC) after endoscopic submucosal dissection (ESD). However, it is unclear whether additional radiotherapy can improve patient survival. This study aimed to evaluate the efficacy of adjuvant radiotherapy after ESD for pT1b ESCC.This was a multicenter, cross-sectional study involving 11 hospitals in China. Between January 2010 and December 2019, T1bN0M0 ESCC patients treated with or without adjuvant radiotherapy following ESD were included. Survival between groups was compared.Overall, 774 patients were screened, and 161 patients were included. Forty-seven (29.2%) patients received adjuvant radiotherapy following ESD (RT group) and 114 (70.8%) underwent ESD alone (non-RT group). There were no significant differences in overall survival (OS) and disease-free survival (DFS) between the RT and non-RT groups. Lymphovascular invasion (LVI) was the only prognostic factor. In the LVI+ group, adjuvant radiotherapy significantly improved survival (5-year OS: 91.7% vs. 59.5%, P = 0.050; 5-year DFS: 92.9% vs. 42.6%, P = 0.010). In the LVI- group, adjuvant radiotherapy did not improve survival (5-year OS: 83.5% vs. 93.9%, P = 0.148; 5-year DFS: 84.2% vs. 84.7%, P = 0.907). The standardized mortality ratios were 1.52 (95% CI, 0.04-8.54) in LVI+ group with radiotherapy and 0.55 (95% CI, 0.15-1.42) in LVI- group without radiotherapy.Adjuvant radiotherapy could improve survival in pT1b ESCC with LVI+ other than LVI- after ESD. Selective adjuvant radiotherapy based on LVI status achieved survival rates similar to those of the general population.Copyright © 2023 by The American College of Gastroenterology.

基金：
CAMS Innovation Fund for Medical Sciences (CIFMS) [grant number 2020-I2M-C & T-B-074], Beijing Hope Run Special Fund of Cancer Foundation of China [grant number LC2019B12], Linghang Cancer Research Fund Project of CSCO [grant number Y-2019AZMS-0426] and Capital’s Funds for Health Improvement and Research [grant number 2022-1-4022].
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 2 区 胃肠肝病学
最新[2025]版：
大类 | 1 区 医学
小类 | 2 区 胃肠肝病学
JCR分区：
出版当年[2023]版：
Q1 GASTROENTEROLOGY & HEPATOLOGY
最新[2023]版：
Q1 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of VIP Medical Services & Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
共同第一作者：
通讯作者：
通讯机构： [12]Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [15]Department of Endoscopy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [*1]Panjiayuan Nanli #17, Chaoyang District, Beijing
推荐引用方式(GB/T 7714)：
Yang Xu,Zhao Lina,Shi Anhui,et al.Radiotherapy Improves Survival of Patients with Lymphovascular Invasion in pT1b Esophageal Squamous Cell Cancer after Endoscopic Submucosal Dissection[J].AMERICAN JOURNAL OF GASTROENTEROLOGY.2023,118(8):1344-1352.doi:10.14309/ajg.0000000000002257.
APA：
Yang Xu,Zhao Lina,Shi Anhui,Chen Cong,Cao Jianzhong...&Hui Zhouguang.(2023).Radiotherapy Improves Survival of Patients with Lymphovascular Invasion in pT1b Esophageal Squamous Cell Cancer after Endoscopic Submucosal Dissection.AMERICAN JOURNAL OF GASTROENTEROLOGY,118,(8)
MLA：
Yang Xu,et al."Radiotherapy Improves Survival of Patients with Lymphovascular Invasion in pT1b Esophageal Squamous Cell Cancer after Endoscopic Submucosal Dissection".AMERICAN JOURNAL OF GASTROENTEROLOGY 118..8(2023):1344-1352

相关文献

[1]Comparison between endoscopic mucosal resection with a cap and endoscopic submucosal dissection for rectal neuroendocrine tumors [2]Endoscopic submucosal dissection in a patient with gastric submucosal parasitic granuloma Case [3]上消化道内镜黏膜下剥离术后食管狭窄的原因及防治 [4]Endoscopic diagnosis of early-stage primary esophageal small cell carcinoma: Report of two cases. [5]Is postoperative adjuvant radiotherapy necessary for patients with esophageal cancer after neoadjuvant chemoradiotherapy? An analysis based on the SEER database [6]术后pN0期食管癌辅助性放疗研究进展 [7]Efficacy and Safety of Toripalimab Combined with Radiotherapy and S-1 Followed by Adjuvant Toripalimab Maintenance Therapy for Older Patients with Esophageal Cancer [8]Survival Study of Adjuvant Radiotherapy and Chemotherapy after Definitive Surgery of Locally Advanced Esophageal Carcinoma [9]食管癌术后吻合口生物力学分析及加强措施 [10]食管胃吻合口瘘防治进展

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号